Vir Biotechnology, Inc. (VIR) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US92764N1028
Vir Biotechnology, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 68.56 m USD |
| Gross profit | 68.53 m USD |
| Operating income | -479.33 m USD |
| EBIT | -478.01 m USD |
| Net income | -437.99 m USD |
| Diluted EPS – continuing operations | -3.16 USD |
Full history since 2016, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
More stocks
- Jiangsu Shemar Electric Co Ltd (603530.SS)
- Freehold Royalties Ltd (FRU.TO)
- Shenzhen Kangtai Biological Products Co Ltd (300601.SZ)
- Zhejiang Taotao Vehicles Co. Ltd. A (301345.SZ)
- Oxford Instruments PLC (OXIG.L)
- Netmarble Games Corp (251270.KS)
- Shanghai Baosight Software Co Ltd B (900926.SS)
- Sendas Distribuidora S.A. (ASAI3.SA)
- Gambol Pet Group Co Ltd Class A (301498.SZ)
- Ashmore Group PLC (ASHM.L)
- Savills PLC (SVS.L)
- Paragon Banking Group PLC (PAG.L)
Not investment advice. All data without warranty, price as of 28.10.2026. Details in the risk notice.